The Extended Gestational Age Medical Abortion Study

NCT ID: NCT00997347

Last Updated: 2012-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open-label, comparative study will compare the efficacy, safety, and acceptability of 200 mg mifepristone followed in 24-48 hours by 800mcg buccal misoprostol or 400mcg sublingual misoprostol for termination of pregnancy in existing outpatient early medical abortion services among women 57-63 days' versus 64-70 days' gestation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medical Abortion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

64-70 days' gestational age

Women whose pregnancies are estimated to have a gestational age of 64-70 days

Group Type EXPERIMENTAL

Mifepristone and misoprostol

Intervention Type DRUG

200 mg oral mifepristone

800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone

57-63 days' gestational age

Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mifepristone and misoprostol

200 mg oral mifepristone

800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* intrauterine pregnancy of greater than 56 days and less than 71 days
* eligible for medical abortion according to study doctor assessment
* willing and able to sign consent forms
* speak English or Spanish (in US sites); speak the local language(s) (in international sites)
* agree to comply with the study procedures and visit schedule
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gynuity Health Projects

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yael Swica, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Gynuity Health Projects

Hillary Bracken, PhD

Role: PRINCIPAL_INVESTIGATOR

Gynuity Health Projects

Beverly Winikoff, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Gynuity Health Projects

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Presidential Women's Center

West Palm Beach, Florida, United States

Site Status

Family Planning Associates Medical Group

Chicago, Illinois, United States

Site Status

Planned Parenthood League of Massachusetts

Boston, Massachusetts, United States

Site Status

Planned Parenthood, Minnesota, North Dakota, South Dakota

Saint Paul, Minnesota, United States

Site Status

Planned Parenthood of New York City

New York, New York, United States

Site Status

Planned Parenthood, Central Texas

Waco, Texas, United States

Site Status

Zhordania Institute of Human Reproduction

Tbilisi, , Georgia

Site Status

Government Medical College (GMC)

Nagpur, , India

Site Status

Naval Nursing Home

Solapur, , India

Site Status

La Rabta Maternity Hospital

Tunis, , Tunisia

Site Status

Central District Maternity House

Odesa, , Ukraine

Site Status

Maternity Hospital No.2

Simferopol, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Georgia India Tunisia Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Winikoff B, Dzuba IG, Chong E, Goldberg AB, Lichtenberg ES, Ball C, Dean G, Sacks D, Crowden WA, Swica Y. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012 Nov;120(5):1070-6. doi: 10.1097/aog.0b013e31826c315f.

Reference Type DERIVED
PMID: 23090524 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1.2.2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.